---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-000362"
form_type: "8-K"
ticker: "KALA"
cik: "0001479419"
company_name: "KALA BIO, Inc."
filed_at: "2023-01-19T23:59:59+00:00"
generated_at: "2026-06-20T13:04:48.734652+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kala Pharma enters $40M ATM equity facility with Jefferies, prepays $10M Oxford loan

## Summary
- New Open Market Sale Agreement with Jefferies for up to $40M in common stock at market prices; Jefferies gets up to 3% commission.
- Prior $75M ATM facility fully utilized (565,974 shares sold for $75M gross proceeds); terminated Jan 10, 2023.
- Company notified Oxford Finance of intent to prepay $5M by June 30, 2023 and $5M by Jan 31, 2024, reducing loan principal to ~$34M.
- Prepayments include final payment fees and accrued interest; scheduled for Feb 2, 2023.

## SEC filing metadata
- accession: 0001558370-23-000362
- form_type: 8-K
- ticker: KALA
- cik: 0001479419
- company_name: KALA BIO, Inc.
- filed_at: 2023-01-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479419/000155837023000362/0001558370-23-000362-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479419/000155837023000362/kala-20230118x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-000362
- JSON: https://secwatch.observer/filing/0001558370-23-000362.json
- Plain text: https://secwatch.observer/filing/0001558370-23-000362.txt

## Key facts
- Material Agreements
  KALA BIO, Inc. entered into Open Market Sale Agreement with Jefferies LLC valued at $40,000,000 (effective 2023-01-19).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Jefferies LLC
  - Value: $40,000,000
  - Effective: 2023-01-19
  source text: On January 19, 2023, Kala Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), entered into an Open Market Sale Agreement SM (the “ Sales Agreement ”) with Jefferies LLC, as agent (“ Jefferies ”), pursuant to which the Company may offer and sell shares of its common stock, $0.001 par value per share (the “ Common Stock ”), from time to time through Jefferies.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479419/000155837023000362/0001558370-23-000362-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.